198 related articles for article (PubMed ID: 35040442)
1. Using autoantibody signatures to define cancer risk in dermatomyositis.
Turnier JL; Kahlenberg JM
J Clin Invest; 2022 Jan; 132(2):. PubMed ID: 35040442
[TBL] [Abstract][Full Text] [Related]
2. Serum levels of anti-transcriptional intermediary factor 1-γ autoantibody associated with the clinical, pathological characteristics and outcomes of patients with dermatomyositis.
Zhang L; Yang H; Yang H; Liu H; Tian X; Jiang W; Peng Q; Wang G; Lu X
Semin Arthritis Rheum; 2022 Aug; 55():152011. PubMed ID: 35489170
[TBL] [Abstract][Full Text] [Related]
3. Autoantibody Markers of Increased Risk of Malignancy in Patients with Dermatomyositis.
Marzęcka M; Niemczyk A; Rudnicka L
Clin Rev Allergy Immunol; 2022 Oct; 63(2):289-296. PubMed ID: 35147864
[TBL] [Abstract][Full Text] [Related]
4. Anti-TIF1-γ autoantibodies: warning lights of a tumour autoantigen.
De Vooght J; Vulsteke JB; De Haes P; Bossuyt X; Lories R; De Langhe E
Rheumatology (Oxford); 2020 Mar; 59(3):469-477. PubMed ID: 31883334
[TBL] [Abstract][Full Text] [Related]
5. Immune responses to CCAR1 and other dermatomyositis autoantigens are associated with attenuated cancer emergence.
Fiorentino DF; Mecoli CA; Rosen MC; Chung LS; Christopher-Stine L; Rosen A; Casciola-Rosen L
J Clin Invest; 2022 Jan; 132(2):. PubMed ID: 35040440
[TBL] [Abstract][Full Text] [Related]
6. Clinical significance of serum levels of anti-transcriptional intermediary factor 1-γ antibody in patients with dermatomyositis.
Ikeda N; Yamaguchi Y; Kanaoka M; Ototake Y; Akita A; Watanabe T; Aihara M
J Dermatol; 2020 May; 47(5):490-496. PubMed ID: 32103537
[TBL] [Abstract][Full Text] [Related]
7. Myositis-specific autoantibodies and their association with malignancy in Italian patients with polymyositis and dermatomyositis.
Ceribelli A; Isailovic N; De Santis M; Generali E; Fredi M; Cavazzana I; Franceschini F; Cantarini L; Satoh M; Selmi C
Clin Rheumatol; 2017 Feb; 36(2):469-475. PubMed ID: 27761751
[TBL] [Abstract][Full Text] [Related]
8. Identification of multiple cancer-associated myositis-specific autoantibodies in idiopathic inflammatory myopathies: a large longitudinal cohort study.
Yang H; Peng Q; Yin L; Li S; Shi J; Zhang Y; Lu X; Shu X; Zhang S; Wang G
Arthritis Res Ther; 2017 Nov; 19(1):259. PubMed ID: 29178913
[TBL] [Abstract][Full Text] [Related]
9. Anti-MDA5 autoantibodies associated with juvenile dermatomyositis constitute a distinct phenotype in North America.
Mamyrova G; Kishi T; Shi M; Targoff IN; Huber AM; Curiel RV; Miller FW; Rider LG;
Rheumatology (Oxford); 2021 Apr; 60(4):1839-1849. PubMed ID: 33140079
[TBL] [Abstract][Full Text] [Related]
10. [Autoantibody profile in myositis].
Allenbach Y; Benveniste O
Rev Med Interne; 2014 Jul; 35(7):437-43. PubMed ID: 24387952
[TBL] [Abstract][Full Text] [Related]
11. Frequency, mutual exclusivity and clinical associations of myositis autoantibodies in a combined European cohort of idiopathic inflammatory myopathy patients.
Betteridge Z; Tansley S; Shaddick G; Chinoy H; Cooper RG; New RP; Lilleker JB; Vencovsky J; Chazarain L; Danko K; Nagy-Vincze M; Bodoki L; Dastmalchi M; Ekholm L; Lundberg IE; McHugh N;
J Autoimmun; 2019 Jul; 101():48-55. PubMed ID: 30992170
[TBL] [Abstract][Full Text] [Related]
12. The spectrum and clinical significance of myositis-specific autoantibodies in Chinese patients with idiopathic inflammatory myopathies.
Li S; Ge Y; Yang H; Wang T; Zheng X; Peng Q; Lu X; Wang G
Clin Rheumatol; 2019 Aug; 38(8):2171-2179. PubMed ID: 30863950
[TBL] [Abstract][Full Text] [Related]
13. Anti-transcriptional intermediary factor 1 gamma antibodies in cancer-associated myositis: a longitudinal study.
Dani L; Holmqvist M; Martínez MA; Trallero-Araguas E; Dastmalchi M; Svensson J; Labrador-Horrillo M; Selva-O'Callaghan A; Lundberg IE
Clin Exp Rheumatol; 2020; 38(1):67-73. PubMed ID: 31365334
[TBL] [Abstract][Full Text] [Related]
14. Development of dermatomyositis after anti-transcriptional intermediary factor 1-γ antibody seroconversion during treatment for small cell lung cancer.
Sato Y; Tanino Y; Nikaido T; Togawa R; Kawamata T; Watanabe N; Sato R; Yamada R; Onuma T; Tomita H; Saito M; Rikimaru M; Morimoto J; Suzuki Y; Minemura H; Saito J; Kanazawa K; Yamada S; Hashimoto Y; Shibata Y
BMC Pulm Med; 2022 May; 22(1):191. PubMed ID: 35549684
[TBL] [Abstract][Full Text] [Related]
15. [Comparison of clinical and immunological features between clinically amyopathic dermatomyositis and typical dermatomyositis].
Gan YZ; Li YH; Zhang LH; Ma L; He WW; Jin YB; An Y; Li ZG; Ye H
Beijing Da Xue Xue Bao Yi Xue Ban; 2020 Dec; 52(6):1001-1008. PubMed ID: 33331305
[TBL] [Abstract][Full Text] [Related]
16. A Case in Which Breast Cancer Developed at the Same Time As Dermatomyositis, and the Onset of New Cancer Was Able to Be Predicted by the Exacerbating Skin Symptoms and Parallel Increase in the Anti-TIF1-γ Antibody Levels.
Akagi H; Wada T
Intern Med; 2023; 62(20):3057-3062. PubMed ID: 37839875
[TBL] [Abstract][Full Text] [Related]
17. Myositis autoantibodies in Iranian myositis patients: assessment the frequency and clinical relevancy.
Ebrahimi M; Rostamian A; Rafiei-Latianee R; Najafizadeh SR; Movaseghi S; Faezi ST; Ghazanfari T
Clin Rheumatol; 2022 Feb; 41(2):533-539. PubMed ID: 34514533
[TBL] [Abstract][Full Text] [Related]
18. Paraneoplastic anti-TIF1-gamma-positive dermatomyositis as expression of cervical squamous cell carcinoma recurrence.
van Erp MAJM; Slaats FMA; Emmen JMA; van Hamont D
BMJ Case Rep; 2024 Jan; 17(1):. PubMed ID: 38262717
[TBL] [Abstract][Full Text] [Related]
19. A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups.
Love LA; Leff RL; Fraser DD; Targoff IN; Dalakas M; Plotz PH; Miller FW
Medicine (Baltimore); 1991 Nov; 70(6):360-74. PubMed ID: 1659647
[TBL] [Abstract][Full Text] [Related]
20. Clinical features of anti-TIF1-α antibody-positive dermatomyositis patients are closely associated with coexistent dermatomyositis-specific autoantibodies and anti-TIF1-γ or anti-Mi-2 autoantibodies.
Muro Y; Ishikawa A; Sugiura K; Akiyama M
Rheumatology (Oxford); 2012 Aug; 51(8):1508-13. PubMed ID: 22539482
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
